guadecitabine
Small moleculeexperimental
Clinical trial activity
33 trials · 31 clinical orgs · 0 marketing orgs
Phase 1
16
Phase 2
24
Phase 3
3
Phase 4
0
Earliest trial started Dec 1, 2010 (NCT01261312)
Timeline
Indications
Studied for
- Bile Duct Neoplasms · Phase 1
- Carcinoma, Hepatocellular · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carcinoma, Renal Cell · Phase 2
- Carcinoma, Transitional Cell · Phase 2
- Cholangiocarcinoma · Phase 1
- Chondrosarcoma · Phase 2
- Colorectal Neoplasms · Phase 1/Phase 2
- Fallopian Tube Neoplasms · Phase 2
- Gallbladder Neoplasms · Phase 1
- Gastrointestinal Stromal Tumors · Phase 2
- Hamartoma · Phase 2
- Kidney Neoplasms · Phase 2
- Leukemia, Myeloid, Acute · Phase 3
- Leukemia, Myelomonocytic, Chronic · Phase 3
- Lung Neoplasms · Phase 1
- Melanoma · Phase 2
- Methylation · Phase 1/Phase 2
- Myelodysplastic Syndromes · Phase 3
- Myeloproliferative Disorders · Phase 2
- Neoplasm, Residual · Phase 2
- Neoplasms, Germ Cell and Embryonal · Phase 1
- Ovarian Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 1
- Paraganglioma · Phase 2
- Pheochromocytoma · Phase 2
- Prostatic Neoplasms, Castration-Resistant · Phase 1
- Small Cell Lung Carcinoma · Phase 2
- Testicular Neoplasms · Phase 1
Mechanism of action
- DNA (cytosine-5)-methyltransferase 1INHIBITOR
DNMT1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Nc1ncn([C@H]2C[C@H](OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3O)[C@@H](CO)O2)c(=O)n1- Mol. weight
- 557.42 g/mol
- Lipinski Ro5
- 3 violation(s)
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Prodrug
Sources
- ChEMBLCHEMBL3544916 ↗
Also known as
- guadecitabine
- guadecitabine
- guadecitabine
- guadecitabine
- guadecitabine
- sgi-110
- sgi-110
- sgi-110
- sgi-110
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04340843 | Phase 2 | Apr 10, 2020 | National Cancer Institute (NCI), Yale University |
| NCT04250246 | Phase 2 | Mar 31, 2020 | Astex Pharmaceuticals, Inc., Bristol-Myers Squibb, Italian Network for Tumor Biotherapy, University of Siena |
| NCT03913455 | Phase 2 | May 31, 2019 | Astex Pharmaceuticals, Inc., Hoosier Cancer Research Network, Indiana University |
| NCT03576963 | Phase 1/Phase 2 (Phase 2) | Oct 22, 2018 | Astex Pharmaceuticals, Inc., Bristol-Myers Squibb, National Cancer Institute (NCI), University of Southern California |
| NCT03454984 | Phase 2 | Sep 30, 2018 | Groupe Francophone des Myelodysplasies, Hôpital Saint Louis |
| NCT03603964 | Phase 2 | Jul 23, 2018 | Astex Pharmaceuticals, Inc. |
| NCT03257761 | Phase 1 | Feb 7, 2018 | National Cancer Institute (NCI), University of Southern California, Van Andel Research Institute |
| NCT03308396 | Phase 1/Phase 2 (Phase 2) | Dec 19, 2017 | AstraZeneca, Big Ten Cancer Research Consortium, University of Michigan |
| NCT03206047 | Phase 1/Phase 2 (Phase 2) | Sep 22, 2017 | National Cancer Institute (NCI), State University of New York, Buffalo |
| NCT03220477 | Phase 1 | Aug 4, 2017 | Astex Pharmaceuticals, Inc., Memorial Sloan-Kettering Cancer Center, Merck, Mirati Therapeutics Inc., Stand Up To Cancer, Van Andel Research Institute |
| NCT03179943 | Phase 2 | Aug 1, 2017 | Temple University |
| NCT03165721 | Phase 2 | Jul 4, 2017 | National Cancer Institute (NCI) |
| NCT03085849 | Phase 1 | Apr 1, 2017 | Columbia University |
| NCT02920008 | Phase 3 | Mar 16, 2017 | Astex Pharmaceuticals, Inc. |
| NCT02998567 | Phase 1 | Dec 1, 2016 | Astex Pharmaceuticals, Inc., Merck, Royal Marsden Hospital NHS Trust, University of London |
| NCT02901899 | Phase 2 | Nov 1, 2016 | Astex Pharmaceuticals, Inc., Merck, National Cancer Institute (NCI), Northwestern University |
| NCT02935361 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2016 | National Cancer Institute (NCI), University of Southern California |
| NCT02892318 | Phase 1 | Oct 31, 2016 | Roche |
| NCT02907359 | Phase 3 | Oct 1, 2016 | Astex Pharmaceuticals, Inc. |
| NCT02684162 | Phase 2 | Jun 1, 2016 | Astex Pharmaceuticals, Inc., University of Texas at Houston |
Showing 20 of 33 trials
Page 1 / 2
Organizations
Research & Development (31)
31 organizations
Page 1 / 2